Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned an average rating of “Moderate Buy” from the seventeen ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $30.91.

Several analysts have issued reports on BCAX shares. Mizuho upped their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Morgan Stanley reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 20th. The Goldman Sachs Group downgraded Bicara Therapeutics from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $20.00 to $8.00 in a research report on Friday. BMO Capital Markets started coverage on Bicara Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, HSBC lowered Bicara Therapeutics to an “equal weight” rating in a research note on Tuesday, September 22nd.

Insider Activity

In other news, CEO Claire Mazumdar sold 10,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares in the company, valued at $10,133,012.96. This represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the sale, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 58,750 shares of company stock worth $1,554,800 over the last three months. 13.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $63,000. Profund Advisors LLC boosted its position in Bicara Therapeutics by 7.2% during the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after acquiring an additional 1,140 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Bicara Therapeutics by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock worth $224,000 after acquiring an additional 1,617 shares during the last quarter. Sterling Capital Management LLC raised its holdings in Bicara Therapeutics by 457.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock valued at $26,000 after acquiring an additional 1,138 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new position in Bicara Therapeutics in the 2nd quarter valued at $499,000.

Bicara Therapeutics Trading Down 6.2%

Shares of NASDAQ BCAX opened at $9.13 on Friday. The company’s 50-day moving average price is $19.74 and its 200 day moving average price is $21.16. Bicara Therapeutics has a 52 week low of $8.36 and a 52 week high of $30.99. The stock has a market cap of $604.13 million, a price-to-earnings ratio of -2.95 and a beta of -0.70.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, research analysts expect that Bicara Therapeutics will post -3.49 earnings per share for the current year.

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.